<a href="https://www.fiercebiotech.com/cro/executive-assistant-chief-executive-charles-river-ceo-birgit-girshick-next-big-transition-cro" hreflang="en">From executive assistant to chief executive: Charles River CEO Birgit Girshick on ‘the next big transition’ in the CRO industry</a>
Birgit Girshick, CEO of Charles River Laboratories, emphasizes the importance of technology and increased collaboration in the contract research organization (CRO) industry to enhance data sharing and improve drug development outcomes. As she leads the company through a transition period following recent challenges, Girshick aims to maintain employee morale and align CRL’s mission with client goals to foster better health outcomes.
Charles River Laboratories is enhancing client collaboration through a new data-sharing platform that allows real-time access to study data. This initiative not only speeds up insight generation but also enables clients to apply their own AI and computational models, potentially leading to accelerated drug development and improved health outcomes. For an expert in healthtech and biotech, this reflects a significant trend toward increased transparency and technological integration in CRO operations, highlighting opportunities for investment or partnership in digital health platforms that facilitate seamless data exchange and analysis.